Janux Therapeutics (Janux Therapeutics) Price-to-Tangible-Book : 7.06 (As of Apr. 29, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Janux Therapeutics Price-to-Tangible-Book?

As of today (2024-04-29), Janux Therapeutics's share price is $52.555. Janux Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $7.45. Hence, Janux Therapeutics's Price to Tangible Book Ratio of today is 7.06.

The historical rank and industry rank for Janux Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

JANX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.44 Med: 1.71 Max: 7.12
Current: 7.05

During the past 5 years, Janux Therapeutics's highest Price to Tangible Book Ratio was 7.12. The lowest was 1.44. And the median was 1.71.

JANX's Price-to-Tangible-Book is ranked worse than
79.92% of 1220 companies
in the Biotechnology industry
Industry Median: 2.65 vs JANX: 7.05

A closely related ratio is called PB Ratio. As of today, Janux Therapeutics's share price is $52.555. Janux Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $7.45. Hence, Janux Therapeutics's P/B Ratio of today is 7.06.

Janux Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Janux Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Janux Therapeutics Price-to-Tangible-Book Chart

Janux Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

2.22

1.71

1.44

Janux Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial												1.71	1.63	1.66	1.33	1.44

Competitive Comparison of Janux Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Janux Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Janux Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Janux Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Janux Therapeutics's Price-to-Tangible-Book falls into.

Janux Therapeutics Price-to-Tangible-Book Calculation

Janux Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	52.555	/	7.445
	=	7.06

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Janux Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Janux Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Janux Therapeutics (Janux Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Janux Therapeutics Inc (NAS:JANX) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

10955 Vista Sorrento Parkway, Suite 200, San Diego, CA, USA, 92130

Website

https://www.januxrx.com

Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.

Executives

Tighe Reardon	10 percent owner, officer: Acting Chief Financial Officer	C/O SYNTHORX, INC., 11099 NORTH TORREY PINES ROAD, SUITE 190, LA JOLLA CA 92037
Avalon Ventures Xi, L.p.	10 percent owner	1134 KLINE STREET, LA JOLLA CA 92037
Jay Lichter	director, 10 percent owner	C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Nexus Fund Ii, L.p.	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Charles M. Winter	officer: Chief Technical Officer	C/O JANUX THERAPEUTICS, INC., 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO CA 92130
Winston Kung	director	C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Byron Robinson	officer: Chief Strategy Officer	C/O JANUX THERAPEUTICS, INC., 11099 N. TORREY PINES ROAD, SUITE 290, LA JOLLA CA 92037
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson	director	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Orbimed Capital Gp Viii Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Orbimed Capital Gp Vii Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Alana B. Mcnulty	director	C/O LUMENA PHARMACEUTICALS, INC., 12531 HIGH BLUFF DRIVE, SUITE 110, SAN DIEGO CA 92130
Ronald W Barrett	director	C/O XENOPORT, INC., 3410 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051